Bioiberica Heparin Science to participate in the DCAT Week 2018
- Bioiberica’s Business Unit dedicated to the production of Heparin has the objective of establishing strategic alliances and finding new business opportunities in the US market
- This is the largest professional and business meeting of the American pharmaceutical industry, which will include high level meetings, networking sessions and educational programs
Heparin Science, Bioibérica's Business Unit dedicated to the research, development, manufacturing and marketing of the Heparin molecule, will participate in the DCAT Week that takes place from March 19 to 22 in New York, with the objective of establishing strategic alliances and find new business opportunities in the US market.
Hosted by the Drug Chemical and Associated Technologies (DCAT) association, this is the largest professional and business meeting of the American pharma industry, and includes high level meetings, networking sessions and educational programs. Its unique model brings industry CEOs, presidents, global marketing directors and supply chain managers from the entire pharmaceutical world.
Heparin is the product in which Bioibérica has been specializing since its foundation in 1975, becoming the world leader in the production of this active pharmaceutical ingredient. Specifically, one out of every five doses of heparin administered worldwide is developed and manufactured in Spain by Bioibérica, which already has eight first process plants worldwide.
Related News
A crucial initiative to prevent shortages of critical medicines in the European Union.
The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by
- Bioiberica produces 20% of the world's Heparin API.
- Heparin saves around a hundred million lives every year.
- One out of every 5 doses of heparin administered in the world comes from Bioiberica.